Bristol-Myers Squibb Company stock price

Bristol-Myers Squibb Company latest news:


  • 12/13/2017 16:34:22

    BRIEF-Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting ...

    Bristol-Myers Squibb Co(BMY): * BRISTOL-MYERS SQUIBB GRANTED EXCLUSIVE LICENSE BY ONO PHARMACEUTICAL FOR MULTIPLE PROGRAMS TARGETING IMMUNO-SUPPRESSIVE FACTORS IN THE TUMOR MICROENVIRONMENT. * Bristol-Myers Squibb Co(BMY) - BRISTOL-MYERS SQUIBB WILL MAKE AN UPFRONT PAYMENT OF $40 MILLION TO ONO.

  • 12/13/2017 16:34:07

    BRIEF-Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting Immuno-Suppressive Factors In The Tumor Microenvironment

    * BRISTOL-MYERS SQUIBB GRANTED EXCLUSIVE LICENSE BY ONO PHARMACEUTICAL FOR MULTIPLE PROGRAMS TARGETING IMMUNO-SUPPRESSIVE FACTORS IN THE TUMOR MICROENVIRONMENT

  • 12/13/2017 15:44:48

    BRIEF-U.S. FDA Accepts Bristol-Myers Squibb’S Application For Opdivo (Nivolumab) Plus Yervoy (Ipilimumab)

    Bristol-Myers Squibb Co(BMY): * U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO PLUS YERVOY IN INTERMEDIATE- AND POOR-RISK PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AND GRANTS PRIORITY REVIEW. * Bristol-Myers Squibb Co (BMY) - APPLICATION HAS AN ACTION DATE OF APRIL 16, 2018.

  • 10/26/2017 09:25:46

    UPDATE 1-Bristol-Myers sales in line, but profit margins worsen

    Oct 26 (Reuters) - Bristol-Myers Squibb Co reported a 7 percent increase in third-quarter revenue as sales of key drugs met Wall Street expectations, but earnings fell short due to higher costs and an inventory write-off, sending shares down 4 percent.

  • 10/16/2017 01:21:36

    BRIEF-Bristol-Myers ‍announces data for Opdivo and Opdivo plus Yervoy in previously treated small cell lung cancer​

    Bristol-Myers Squibb Co(BMY). * Bristol-Myers Squibb Co(BMY) ‍announced data evaluating Opdivo and Opdivo plus Yervoy in previously treated small cell lung cancer​. * Bristol-Myers Squibb Co (BMY) says ‍in patients with high tmb who received opdivo plus yervoy, 62% were alive at one year​. * Bristol-Myers Squibb Co (BMY) says ‍in patients with high tmb who received opdivo, 35% were alive at one year​ Sou...

  • More trends:

    Bristow Group IncBRS | Brixmor Property Group Inc.BRX | Broadridge Financial SolutionsBR | Brookdale Senior Living Inc.BKD | Brookfield Asset Management IncBAM | Brookfield Canada Office PropertiesBOXC | Brookfield DTLA Inc.DTLA^ | Brookfield Global Listed Infrastructure Income FunINF | Brookfield High Income Fund Inc.HHY | Brookfield Infrastructure Partners LPBIP |